|
1
|
Kato M and Asaka M: Recent knowledge of
the relationship between Helicobacter pylori and gastric cancer and
recent progress of gastroendoscopic diagnosis and treatment for
gastric cancer. Jpn J Clin Oncol. 40:828–837. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ikeda F and Kiyohasa Y: The epidemiology
of gastric cancer: The Hisayama Study. Fukuoka Igaku Zasshi.
106:195–201. 2015.(In Japanese). PubMed/NCBI
|
|
3
|
De Milito A and Fais S: Tumor acidity,
chemoresistance and proton pump inhibitors. Future Oncol.
1:779–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bai ZG, Qu X, Han W, Ma XM, Zhao XM and
Zhang ZT: Expression of taxol resistance gene 1 correlates with
gastric cancer patient clinical outcome and induces taxol
resistance. Mol Med Rep. 3:1071–1078. 2010.PubMed/NCBI
|
|
7
|
Zhang H, Qu X, Ma X, Wang T, Yang Y, Ge Z,
Zhang Z, Bai Z, Gao Y, Yuan Z and Wang Z: TXR1 and TSP1 expression
varies by the molecular subtypes of breast cancer patients who
received previous docetaxel-based first-line chemotherapy. Exp Biol
Med (Maywood). 241:1919–1923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Papadaki C, Tsaroucha E, Kaklamanis L,
Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E,
Georgoulias V and Souglakos J: Correlation of BRCA1, TXR1 and TSP1
mRNA expression with treatment outcome to docetaxel-based
first-line chemotherapy in patients with advanced/metastatic
non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bi W, Wang Y, Sun G, Zhang X, Wei Y, Li L
and Wang X: Paclitaxel-resistant HeLa cells have up-regulated
levels of reactive oxygen species and increased expression of taxol
resistance gene 1. Pak J Pharm Sci. 27:871–878. 2014.PubMed/NCBI
|
|
10
|
Papadaki C, Mavroudis D, Trypaki M,
Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E,
Georgoulias V and Souglakos J: Tumoral expression of TXR1 and TSP1
predicts overall survival of patients with lung adenocarcinoma
treated with first-line docetaxel-gemcitabine regimen. Clin Cancer
Res. 15:3827–3833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J,
Yi X, Han S and Zhang Z: Txr1: An important factor in oxaliplatin
resistance in gastric cancer. Med Oncol. 31:8072014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Bai Z, Ma X, Wang T, Yang Y and
Zhang Z: Effects of taxol resistance gene 1 expression on the
chemosensitivity of SGC-7901 cells to oxaliplatin. Exp Ther Med.
11:846–852. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Amerongen R and Berns A: TXR1-mediated
thrombospondin repression: A novel mechanism of resistance to
taxanes? Genes Dev. 20:1975–1981. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Songun I, Keizer HJ, Hermans J,
Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van
Krieken JH and van de Velde CJ: Chemotherapy for operable gastric
cancer: Results of the Dutch randomised FAMTX trial. The Dutch
Gastric Cancer Group (DGCG). Eur J Cancer. 35:558–562. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuruo T, Naito M, Tomida A, Fujita N,
Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of
cancer: Drug resistance, apoptosis and survival signal. Cancer Sci.
94:15–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rueff J and Rodrigues AS: Cancer drug
resistance: A brief overview from a genetic viewpoint. Methods Mol
Biol. 1395:1–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Colloca G, Venturino A and Checcaglini F:
Second-line chemotherapy in metastatic docetaxel-resistant prostate
cancer: A review. Med Oncol. 29:776–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Neill CF, Ormerod MG, Robertson D,
Titley JC, Cumber-Walsweer Y and Kelland LR: Apoptotic and
non-apoptotic cell death induced by cis and trans analogues of a
novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
Br J Cancer. 74:1037–1045. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Henkels KM and Turchi JJ: Induction of
apoptosis in cisplatin-sensitive and -resistant human ovarian
cancer cell lines. Cancer Res. 57:4488–4492. 1997.PubMed/NCBI
|
|
26
|
Ye D, Shuhendler AJ, Pandit P, Brewer KD,
Tee SS, Cui L, Tikhomirov G, Rutt B and Rao J: Caspase-responsive
smart gadolinium-based contrast agent for magnetic resonance
imaging of drug-induced apoptosis. Chem Sci. 4:3845–3852. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lih CJ, Wei W and Cohen SN: Txr1: A
transcriptional regulator of thrombospondin-1 that modulates
cellular sensitivity to taxanes. Genes Dev. 20:2082–2095. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sid B, Sartelet H, Bellon G, El Btaouri H,
Rath G, Delorme N, Haye B and Martiny L: Thrombospondin 1: A
multifunctional protein implicated in the regulation of tumor
growth. Crit Rev Oncol Hematol. 49:245–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
